611,296 Shares in Xeris Biopharma Holdings, Inc. $XERS Acquired by Walleye Capital LLC

Walleye Capital LLC purchased a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 611,296 shares of the company’s stock, valued at approximately $4,841,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Bank of America Corp DE lifted its stake in Xeris Biopharma by 21.8% in the first quarter. Bank of America Corp DE now owns 874,397 shares of the company’s stock valued at $5,072,000 after buying an additional 156,483 shares during the last quarter. Janus Henderson Group PLC grew its position in shares of Xeris Biopharma by 322.8% during the first quarter. Janus Henderson Group PLC now owns 295,489 shares of the company’s stock worth $1,713,000 after acquiring an additional 225,602 shares during the last quarter. California State Teachers Retirement System grew its position in shares of Xeris Biopharma by 19.3% during the first quarter. California State Teachers Retirement System now owns 180,339 shares of the company’s stock worth $1,046,000 after acquiring an additional 29,168 shares during the last quarter. Royal Bank of Canada increased its holdings in shares of Xeris Biopharma by 12.9% in the 1st quarter. Royal Bank of Canada now owns 43,610 shares of the company’s stock valued at $253,000 after acquiring an additional 4,974 shares during the period. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Xeris Biopharma by 59.0% in the 1st quarter. The Manufacturers Life Insurance Company now owns 72,804 shares of the company’s stock valued at $422,000 after acquiring an additional 27,003 shares during the period. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Stock Up 3.2%

XERS opened at $8.60 on Friday. Xeris Biopharma Holdings, Inc. has a 52 week low of $5.25 and a 52 week high of $10.08. The business has a 50 day moving average price of $7.91 and a two-hundred day moving average price of $6.83. The company has a quick ratio of 1.50, a current ratio of 1.45 and a debt-to-equity ratio of 17.00. The company has a market cap of $1.57 billion, a PE ratio of -78.18 and a beta of 0.66.

Xeris Biopharma (NASDAQ:XERS) last announced its earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.19). The company had revenue of $92.10 million during the quarter, compared to analysts’ expectations of $90.12 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. As a group, research analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current year.

Insider Activity

In other Xeris Biopharma news, insider Beth Hecht sold 16,666 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $8.01, for a total value of $133,494.66. Following the transaction, the insider directly owned 1,144,462 shares of the company’s stock, valued at approximately $9,167,140.62. The trade was a 1.44% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barbara-Jean A. Bormann-Kennedy sold 16,000 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $6.09, for a total transaction of $97,440.00. Following the completion of the transaction, the director directly owned 126,500 shares in the company, valued at $770,385. This represents a 11.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 271,499 shares of company stock valued at $2,038,917. 4.35% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms recently commented on XERS. Weiss Ratings downgraded shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Tuesday. Wall Street Zen downgraded shares of Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $10.80.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.